Literature DB >> 22196267

CEACAM1 in malignant melanoma: a diagnostic and therapeutic target.

S Sapoznik1, R Ortenberg, J Schachter, G Markel.   

Abstract

CEACAM1 adhesion molecule is broadly expressed, participates in pivotal cellular and immunological processes and is involved in cancer. Originally identified as a tumor suppressor, it is now known that in several cancers, including malignant melanoma, CEACAM1 expression correlates with tumor progression and poor survival. Here we review the findings connecting CEACAM1 to malignant melanoma, encompassing in-vitro, in-vivo and patients-derived data. A CEACAM1-mediated mechanism used by melanoma cells to evade immune attack is described in detail. Finally, the potential value of CEACAM1 as a melanoma biomarker and therapeutic target is being discussed.
© 2012 Bentham Science Publishers

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22196267     DOI: 10.2174/156802612798919259

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  10 in total

1.  CEACAM1 regulates CD8+ T cell immunity and protects from severe pathology during Citrobacter rodentium induced colitis.

Authors:  Julia Zöller; Jana-Fabienne Ebel; Vishal Khairnar; Verena Schmitt; Robert Klopfleisch; Jana Meiners; Virginia Seiffart; Wiebke Hansen; Jan Buer; Bernhard B Singer; Karl S Lang; Astrid M Westendorf
Journal:  Gut Microbes       Date:  2020-06-10

Review 2.  Evaluating biomarkers in melanoma.

Authors:  Panagiotis Karagiannis; Matthew Fittall; Sophia N Karagiannis
Journal:  Front Oncol       Date:  2015-01-23       Impact factor: 6.244

3.  Serum CEACAM1 Elevation Correlates with Melanoma Progression and Failure to Respond to Adoptive Cell Transfer Immunotherapy.

Authors:  R Ortenberg; S Sapoznik; D Zippel; R Shapira-Frommer; O Itzhaki; A Kubi; D Zikich; M J Besser; J Schachter; G Markel
Journal:  J Immunol Res       Date:  2015-11-25       Impact factor: 4.818

Review 4.  CEACAM1: Expression and Role in Melanocyte Transformation.

Authors:  Gabriela Turcu; Roxana Ioana Nedelcu; Daniela Adriana Ion; Alice Brînzea; Mirela Daniela Cioplea; Lucia Beatrice Jilaveanu; Sabina Andrada Zurac
Journal:  Dis Markers       Date:  2016-08-24       Impact factor: 3.434

5.  Comparative analysis of CEACAM1 expression in thin melanomas with and without regression.

Authors:  Luciana Nichita; Sabina Zurac; Alexandra Bastian; Patricia Stinga; Roxana Nedelcu; Alice Brinzea; Gabriela Turcu; Daniela Ion; Lucia Jilaveanu; Liana Sticlaru; Cristiana Popp; Mirela Cioplea
Journal:  Oncol Lett       Date:  2019-02-25       Impact factor: 2.967

6.  CEACAM1 promotes melanoma cell growth through Sox-2.

Authors:  Rona Ortenberg; Gilli Galore-Haskel; Ilanit Greenberg; Bella Zamlin; Sivan Sapoznik; Eyal Greenberg; Iris Barshack; Camila Avivi; Yulia Feiler; Israel Zan-Bar; Michal J Besser; Ester Azizi; Friedman Eitan; Jacob Schachter; Gal Markel
Journal:  Neoplasia       Date:  2014-06-13       Impact factor: 5.715

7.  CEACAM1-4L Promotes Anchorage-Independent Growth in Melanoma.

Authors:  Stefanie Löffek; Nico Ullrich; André Görgens; Florian Murke; Mara Eilebrecht; Christopher Menne; Bernd Giebel; Dirk Schadendorf; Bernhard B Singer; Iris Helfrich
Journal:  Front Oncol       Date:  2015-10-19       Impact factor: 6.244

8.  Targeting Melanoma with Cancer-Killing Viruses.

Authors:  Tiantian Zhang; Yogesh R Suryawanshi; Helene M Woyczesczyk; Karim Essani
Journal:  Open Virol J       Date:  2017-03-31

9.  Regulation of CEACAM1 Protein Expression by the Transcription Factor ETS-1 in BRAF-Mutant Human Metastatic Melanoma Cells.

Authors:  Karin Kfir-Elirachman; Rona Ortenberg; Bella Vizel; Michal J Besser; Iris Barshack; Jacob Schachter; Yael Nemlich; Gal Markel
Journal:  Neoplasia       Date:  2018-03-17       Impact factor: 5.715

10.  Characterization of murine CEACAM1 in vivo reveals low expression on CD8+ T cells and no tumor growth modulating activity by anti-CEACAM1 mAb CC1.

Authors:  Robbie L McLeod; Minilik H Angagaw; Toya Nath Baral; Liming Liu; Raymond Joseph Moniz; Jason Laskey; SuChun Hsieh; Mike Lee; Jin-Hwan Han; Hassan Issafras; Sarah Javaid; Andrey Loboda; Svetlana Sadekova; Joann A O'Connor; Archie Tse; Juha Punnonen
Journal:  Oncotarget       Date:  2018-10-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.